6.67
Schlusskurs vom Vortag:
$6.47
Offen:
$6.46
24-Stunden-Volumen:
1.30M
Relative Volume:
1.03
Marktkapitalisierung:
$577.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-3.0737
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+8.81%
1M Leistung:
+14.02%
6M Leistung:
-15.14%
1J Leistung:
-67.86%
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KURA
Kura Oncology Inc
|
6.67 | 530.70M | 0 | -168.09M | -138.01M | -2.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-10-14 | Herabstufung | Stifel | Buy → Hold |
2023-12-22 | Eingeleitet | Mizuho | Buy |
2023-08-11 | Eingeleitet | BofA Securities | Buy |
2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
2023-05-17 | Eingeleitet | BTIG Research | Buy |
2023-01-31 | Eingeleitet | Stifel | Buy |
2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-02-15 | Eingeleitet | Jefferies | Buy |
2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
2020-12-03 | Eingeleitet | Stifel | Buy |
2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
2020-05-05 | Eingeleitet | Barclays | Overweight |
2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Kura Oncology Inc. Stock Analysis and ForecastExplosive earnings growth - jammulinksnews.com
What analysts say about Kura Oncology Inc. stockTriple-digit returns - jammulinksnews.com
What drives Kura Oncology Inc. stock priceBreakneck growth rates - jammulinksnews.com
Is Kura Oncology Inc. a good long term investmentConsistently high returns - jammulinksnews.com
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Why Kura Oncology Inc. stock attracts strong analyst attentionFree AI-Driven Trading Strategies - Newser
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - Yahoo Finance
How Kura Oncology Inc. stock performs during market volatilityFree Access to Group - Newser
What makes Kura Oncology Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt? - simplywall.st
Wealth Enhancement Advisory Services LLC Takes $139,000 Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology shares rise 3.34% after-hours following inducement grants to new employees. - AInvest
Kura Oncology's Ziftomenib: A Near-Term FDA Catalyst and a Paradigm Shift for AML Patients - AInvest
Kura Oncology Partners with Kyowa Kirin for Ziftomenib - TipRanks
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.com
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US By Investing.com - Investing.com South Africa
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 3000E Value Index - MarketScreener
Kura Oncology (NASDAQ:KURA) Given Overweight Rating at Cantor Fitzgerald - Defense World
KURA: Cantor Fitzgerald Reiterates Overweight Rating | KURA Stoc - GuruFocus
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Rhumbline Advisers - Defense World
KURA: Wedbush Reiterates 'Outperform' Rating with $36 Price Target | KURA Stock News - GuruFocus
Transcript : Kura Oncology, Inc.Special Call - MarketScreener
Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks
Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Australia
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia - MarketScreener
Kura Oncology stock rises on leukemia drug data (KURA:NASDAQ) - Seeking Alpha
Is The Options Market Predicting A Spike In Kura Oncology Stock? - Barchart.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combinatio - GuruFocus
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment By Investing.com - Investing.com Canada
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):